Generics maker Laurus Lab’s net profit more than doubles in Q1 on strong CDMO business growth
Within CDMO, small molecules segment increased 69%, driven by growth in late-stage clinical and commercial API supplies.
· 7/24/2026, 3:52:07 PM· 2 min read
Within CDMO, small molecules segment increased 69%, driven by growth in late-stage clinical and commercial API supplies.
Read original story →